These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 39123422)

  • 1. Predictive and Prognostic
    Cruz-Montijano M; Amo-Salas M; Cassinello-Espinosa J; García-Carbonero I; Villa-Guzman JC; Garcia-Vicente AM
    Cancers (Basel); 2024 Jul; 16(15):. PubMed ID: 39123422
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Baseline
    García Vicente AM; González García B; Amo-Salas M; García Carbonero I; Cassinello Espinosa J; Gómez-Aldaraví Gutierrez JL; Suarez Hinojosa L; Soriano Castrejón Á
    Clin Transl Oncol; 2019 Mar; 21(3):289-297. PubMed ID: 30006674
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interim and end-treatment
    García Vicente AM; Amo-Salas M; Cassinello Espinosa J; Gómez Díaz R; Soriano Castrejón Á
    Sci Rep; 2021 Apr; 11(1):7389. PubMed ID: 33795764
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fluorine-18-fluorocholine PET/CT parameters predictive for hematological toxicity to radium-223 therapy in castrate-resistant prostate cancer patients with bone metastases: a pilot study.
    Vija Racaru L; Sinigaglia M; Kanoun S; Ben Bouallègue F; Tal I; Brillouet S; Bauriaud-Mallet M; Zerdoud S; Dierickx L; Vallot D; Caselles O; Gabiache E; Pascal P; Courbon F
    Nucl Med Commun; 2018 Jul; 39(7):672-679. PubMed ID: 29790867
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fluorocholine PET/CT predicts skeletal progression, skeletal event and cancer specific survival in patients with biochemical relapse for prostate cancer.
    Zattoni F; Agostini E; Cattaneo F; Maruzzo M; Basso U; Zattoni F; Evangelista L
    Clin Imaging; 2017; 43():110-116. PubMed ID: 28278446
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel nomogram developed for determining suitability of metastatic castration-resistant prostate cancer patients to receive maximum benefit from radium-223 dichloride treatment-Japanese Ra-223 Therapy in Prostate Cancer using Bone Scan Index (J-RAP-BSI) Trial.
    Kitajima K; Igeta M; Kuyama J; Kawahara T; Suga T; Otani T; Sugawara S; Kono Y; Tamaki Y; Seko-Nitta A; Ishiwata Y; Ito K; Toriihara A; Watanabe S; Hosono M; Miyake H; Yamamoto S; Narita M; Daimon T; Yamakado K
    Eur J Nucl Med Mol Imaging; 2023 Apr; 50(5):1487-1498. PubMed ID: 36539508
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Uptake of Radium-223 Dichloride and Early [
    Letellier A; Johnson AC; Kit NH; Savigny JF; Batalla A; Parienti JJ; Aide N
    Mol Imaging Biol; 2018 Jun; 20(3):482-491. PubMed ID: 29027074
    [TBL] [Abstract][Full Text] [Related]  

  • 8. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Early outcome prediction on 18F-fluorocholine PET/CT in metastatic castration-resistant prostate cancer patients treated with abiraterone.
    De Giorgi U; Caroli P; Burgio SL; Menna C; Conteduca V; Bianchi E; Fabbri F; Carretta E; Amadori D; Paganelli G; Matteucci F
    Oncotarget; 2014 Dec; 5(23):12448-58. PubMed ID: 25504434
    [TBL] [Abstract][Full Text] [Related]  

  • 10. (18)F-Fluorocholine PET/CT for early response assessment in patients with metastatic castration-resistant prostate cancer treated with enzalutamide.
    De Giorgi U; Caroli P; Scarpi E; Conteduca V; Burgio SL; Menna C; Moretti A; Galassi R; Rossi L; Amadori D; Paganelli G; Matteucci F
    Eur J Nucl Med Mol Imaging; 2015 Jul; 42(8):1276-83. PubMed ID: 25808631
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prediction of PSA Progression in Castration-Resistant Prostate Cancer Based on Treatment-Associated Change in Tumor Burden Quantified by 18F-Fluorocholine PET/CT.
    Lee J; Sato MM; Coel MN; Lee KH; Kwee SA
    J Nucl Med; 2016 Jul; 57(7):1058-64. PubMed ID: 26912444
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic value of metabolic parameters and clinical impact of ¹⁸F-fluorocholine PET/CT in biochemical recurrent prostate cancer.
    Colombié M; Campion L; Bailly C; Rusu D; Rousseau T; Mathieu C; Ferrer L; Rousseau N; Kraeber-Bodéré F; Rousseau C
    Eur J Nucl Med Mol Imaging; 2015 Nov; 42(12):1784-93. PubMed ID: 26194716
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic Factors in Patients Treated with 223Ra: The Role of Skeletal Tumor Burden on Baseline 18F-Fluoride PET/CT in Predicting Overall Survival.
    Etchebehere EC; Araujo JC; Fox PS; Swanston NM; Macapinlac HA; Rohren EM
    J Nucl Med; 2015 Aug; 56(8):1177-84. PubMed ID: 26069307
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Detection of the Prostate Cancer Bone Metastases: Is It Feasible to Compare 18F-fluorocholine PET/CT, 18F-fluorodeoxyglucose PET/CT and 99mTc-methyl Diphosphonate Bone Scintigraphy?
    Pietrzak AK; Czepczynski R; Wierzchoslawska E; Cholewinski W
    Urol J; 2018 Sep; 15(5):242-247. PubMed ID: 29681049
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Prognostic Value of Quantitative Bone SPECT/CT Before
    Dittmann H; Kaltenbach S; Weissinger M; Fiz F; Martus P; Pritzkow M; Kupferschlaeger J; la Fougère C
    J Nucl Med; 2021 Jan; 62(1):48-54. PubMed ID: 32444369
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Whole-body 18F-fluorocholine (FCH) PET/CT and MRI of the spine for monitoring patients with castration-resistant prostate cancer metastatic to bone: a pilot study.
    Balogova S; Zakoun JB; Michaud L; Khalil A; Tassart M; Esteso A; Kerrou K; Huchet V; Carette MF; Lotz JP; Talbot JN
    Clin Nucl Med; 2014 Nov; 39(11):951-9. PubMed ID: 25140552
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic Value of
    Filippi L; Spinelli GP; Chiaravalloti A; Schillaci O; Equitani F; Bagni O
    Biomedicines; 2020 Nov; 8(12):. PubMed ID: 33266047
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of Baseline and Post-Therapy 18F-FDG PET in the Prognostic Stratification of Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients Treated with Radium-223.
    Bauckneht M; Capitanio S; Donegani MI; Zanardi E; Miceli A; Murialdo R; Raffa S; Tomasello L; Vitti M; Cavo A; Catalano F; Mencoboni M; Ceppi M; Marini C; Fornarini G; Boccardo F; Sambuceti G; Morbelli S
    Cancers (Basel); 2019 Dec; 12(1):. PubMed ID: 31861942
    [No Abstract]   [Full Text] [Related]  

  • 19. Detection of bone metastases in patients with prostate cancer by 18F fluorocholine and 18F fluoride PET-CT: a comparative study.
    Beheshti M; Vali R; Waldenberger P; Fitz F; Nader M; Loidl W; Broinger G; Stoiber F; Foglman I; Langsteger W
    Eur J Nucl Med Mol Imaging; 2008 Oct; 35(10):1766-74. PubMed ID: 18465129
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development and validation of a
    Liu H; Cui Y; Chang C; Zhou Z; Zhang Y; Ma C; Yin Y; Wang R
    BMC Cancer; 2024 Jan; 24(1):150. PubMed ID: 38291351
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.